8-K filing — RELMADA THERAPEUTICS, INC. (RLMD)

Relmada Therapeutics Management to Participate in Jefferies Global Healthcare Conference

Relmada Therapeutics announced that its CEO and CFO will participate in the Jefferies Global Healthcare Conference in London from November 16-19, 2026.

Relmada Therapeutics to Report Third Quarter 2026 Financial Results on November 12, 2026

Relmada Therapeutics, Inc. announced it will host a conference call and webcast on November 12, 2026, to discuss its financial results for the third quarter ended September 30, 2026.

Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026

Relmada Therapeutics announced a conference call scheduled for November 12, 2026 at 4:30 PM ET to discuss third quarter 2026 financial results and business progress. The clinical-stage biotechnology company is advancing its lead candidates NDV-01 and sepranolone for oncology and central nervous system disorders, with NDV-01 progressing toward an IND filing expected by year-end 2026.

Full Transcript: Relmada Therapeutics Q2 2026 Earnings Call

Relmada Therapeutics (NASDAQ:RLMD) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time

Alpha Buying: 4 Biotech Stocks Insiders Are Betting On

I can sit through a biotech presentation and come away convinced that the company has discovered the answer to half the problems in modern medicine. The slides look terrific. The market opportunity is enormous.

Relmada Therapeutics shares are trading higher after Form 4 filings showed its executives bought company stock.